Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | IL1RN | P18510 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791521 | 0.89 | PGR (0.81) | PGRIL1RNKEAP1ERAP1PKM | |
| SCHEMBL8081768 | 0.87 | KEAP1 (0.79) | PGRMAPTIL1RNKEAP1ERAP1 | |
| SCHEMBL28400969 | 0.86 | PGR (0.76) | PGRLMNAMAPTTDP1PKM | |
| SCHEMBL3762452 | 0.85 | PGR (0.74) | PGRIL1RNKEAP1ERAP1PKM | |
| SCHEMBL28121847 | 0.85 | PGR (0.73) | PGRLMNAMAPTTDP1KEAP1 | |
| SCHEMBL97999 | 0.85 | PGR (0.73) | PGRLMNAMAPTTDP1PKM | |
| SCHEMBL7181313 | 0.85 | PGR (0.73) | PGRLMNAMAPTTDP1PKM | |
| SCHEMBL5046668 | 0.85 | PGR (0.73) | PGRLMNAMAPTTDP1PKM | |
| SCHEMBL5329565 | 0.84 | PGR (0.80) | PGRLMNAMAPTTDP1PKM | |
| SCHEMBL30737484 | 0.83 | PGR (0.71) | PGRLMNAMAPTTDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2008142376-A1 | BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | INHIBOX LTD. (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | TNF, CS, COASY | PGR 2436/4885LMNA 3437/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.